Anti-amyloid-β immunotherapy in Alzheimer's disease: Relevance of transgenic mouse studies to clinical trials

Journal of Alzheimer's Disease

Volumn 15, Issue 4, 2008, Pages 555-569

  Wilcock, Donna M ^a   Colton, Carol A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amyloid; Antibody; Cerebral amyloid angiopathy; Clinical trial; Immunization; Inflammation

Indexed keywords

ACC 001; ADJUVANT; ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; B LYMPHOCYTE ANTIBODY; BAPINEUZUMAB; DIPHTHERIA TOXOID CRM197; DNA VACCINE; FREUND ADJUVANT; LY 2062430; MONOCLONAL ANTIBODY; PLACEBO; POLYSORBATE 80; PRESENILIN 1; PRESENILIN 2; QS 21; TAU PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; DISEASE SEVERITY; FRONTOTEMPORAL DEMENTIA; GENE DUPLICATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MICROGLIA; MOUSE; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; VASCULITIS;

EID: 58149375748     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-15404     Document Type: Review

References (83)

1. A.A. Asuni, A. Boutajangout, H. Scholtzova, E. Knudsen, Y.S. Li, D. Quartermain, B. Frangione, T. Wisniewski and E.M. Sigurdsson, Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages, Eur J Neurosci 24 (2006), 2530-2542.
2. B.J. Bacskai, S.T. Kajdasz, R.H. Christie, C. Carter, D. Games, P. Seubert, D. Schenk and B.T. Hyman, Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nat Med 7 (2001), 369-372.
3. B.J. Bacskai, S.T. Kajdasz, M.E. McLellan, D. Games, P. Seubert, D. Schenk and B.T. Hyman, Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy, J Neurosci 22 (2002), 7873-7878.
4. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk and T. Yednock, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nat Med 6 (2000), 916-919.
5. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. Motter, M. Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert and T. Yednock, Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology, Proc Natl Acad Sci U S A 100 (2003), 2023-2028.
6. W.J. Bowers, M.A. Mastrangelo, H.A. Stanley, A.E. Casey, L.J. Milo, Jr. and H.J. Federoff, HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses, Neurobiol Aging 26 (2005), 393-407.
7. M.E. Calhoun, K.H. Wiederhold, D. Abramowski, A.L. Phinney, A. Probst, C. Sturchler-Pierrat, M. Staufenbiel, B. Sommer and M. Jucker, Neuron loss in APP transgenic mice, Nature 395 (1998), 755-756.
8. S. Capsoni, G. Ugolini, A. Comparini, F. Ruberti, N. Berardi and A. Cattaneo, Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice, Proc Natl Acad Sci U S A 97 (2000), 6826-6831.
9. M.A. Chishti, D.S. Yang, C. Janus, A.L. Phinney, P. Horne, J. Pearson, R. Strome, N. Zuker, J. Loukides, J. French, S. Turner, G. Lozza, M. Grilli, S. Kunicki, C. Morissette, J. Paquette, F. Gervais, C. Bergeron, P.E. Fraser, G.A. Carlson, P.S. George-Hyslop and D. Westaway, Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695, J Biol Chem 276 (2001), 21562-21570.
10. C. Colton, S. Wilt, D. Gilbert, O. Chernyshev, J. Snell and M. Dubois-Dalcq, Species differences in the generation of reactive oxygen species by microglia, Mol Chem Neuropathol 28 (1996), 15-20.
11. C.A. Colton, M.P. Vitek, D.A. Wink, Q. Xu, V. Cantillana, M.L. Previti, W.E. Van Nostrand, J.B. Weinberg and H. Dawson, NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease, Proc Natl Acad Sci U S A 103 (2006), 12867-12872.
12. C.A. Colton, D.M. Wilcock, D.A. Wink, J. Davis, W.E. Van Nostrand and M.P. Vitek, The Effects of NOS2 Gene Deletion on Mice Expressing Mutated Human AβPP, J Alzheimers Dis 15 (2008), 571-587.
13. D.H. Cribbs, A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, D. Babikyan, P. Kesslak, T. Kieber-Emmons, C.W. Cotman and M.G. Agadjanyan, Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid, Int Immunol 15 (2003), 505-514.
14. P. Das, V. Howard, N. Loosbrock, D. Dickson, M.P. Murphy and T.E. Golde, Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice, J Neurosci 23 (2003), 8532-8538.
15. K. DaSilva, M.E. Brown, D. Westaway and J. McLaurin, Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology, Neurobiol Dis 23 (2006), 433-444.
16. J. Davis, F. Xu, R. Deane, G. Romanov, M.L. Previti, K. Zeigler, B.V. Zlokovic and W.E. Van Nostrand, Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor, J Biol Chem 279 (2004), 20296-20306.
17. J. Davis, F. Xu, J. Miao, M.L. Previti, G. Romanov, K. Ziegler and W.E. Van Nostrand, Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice, Neurobiol Aging 27 (2006), 946-954.
18. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul and D.M. Holtzman, Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, Proc Natl Acad Sci U S A 98 (2001), 8850-8855.
19. G. DiCarlo, D. Wilcock, D. Henderson, M. Gordon and D. Morgan, Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice, Neurobiol Aging 22 (2001), 1007-1012.
20. J.C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman and S.M. Paul, Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model, Nat Neurosci 5 (2002), 452-457.
21. K. Duff, C. Eckman, C. Zehr, X. Yu, C.M. Prada, J. Pereztur, M. Hutton, L. Buee, Y. Harigaya, D. Yager, D. Morgan, M.N. Gordon, L. Holcomb, L. Refolo, B. Zenk, J. Hardy and S. Younkin, Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1, Nature 383 (1996), 710-713.
22. I. Ferrer, M. Boada Rovira, M.L. Sanchez Guerra, M.J. Rey and F. Costa-Jussa, Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease, Brain Pathol 14 (2004), 11-20.
23. M.E. Frazer, J.E. Hughes, M.A. Mastrangelo, J.L. Tibbens, H.J. Federoff and W.J. Bowers, Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4, Mol Ther 16 (2008), 845-853.
24. D. Frenkel, M. Balass and B. Solomon, N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies, J Neuroimmunol 88 (1998), 85-90.
25. D. Frenkel, M. Balass, E. Katchalski-Katzir and B. Solomon, High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation, J Neuroimmunol 95 (1999), 136-142.
26. D. Frenkel, O. Katz and B. Solomon, Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration, Proc Natl Acad Sci U S A 97 (2000), 11455-11459.
27. D. Frenkel, I. Dewachter, F. Van Leuven and B. Solomon, Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization, Vaccine 21 (2003), 1060-1065.
28. D. Games, D. Adams, R. Alessandrini, R. Barbour, P. Berthelette, C. Blackwell, T. Carr, J. Clemens, T. Donaldson, F. Gillespie and et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature 373 (1995), 523-527.
29. J. Hardy and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297 (2002), 353-356.
30. D.L. Herber, L.M. Roth, D. Wilson, N. Wilson, J.E. Mason, D. Morgan and M.N. Gordon, Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice, Exp Neurol 190 (2004), 245-253.
31. C. Hock, U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R.C. von Rotz, G. Davey, E. Moritz and R.M. Nitsch, Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease, Nat Med 8 (2002), 1270-1275.
32. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, M.A. Wollmer, D. Umbricht, D.J. de Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos and R.M. Nitsch, Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease, Neuron 38 (2003), 547-554.
33. L. Holcomb, M.N. Gordon, E. McGowan, X. Yu, S. Benkovic, P. Jantzen, K. Wright, I. Saad, R. Mueller, D. Morgan, S. Sanders, C. Zehr, K. O'Campo, J. Hardy, C.M. Prada, C. Eckman, S. Younkin, K. Hsiao and K. Duff, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat Med 4 (1998), 97-100.
34. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, R.W. Jones, R. Bullock, S. Love, J.W. Neal, E. Zotova and J.A. Nicoll, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet 372 (2008), 216-223.
35. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang and G. Cole, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science 274 (1996), 99-102.
36. M. Hutton and J. Hardy, The presenilins and Alzheimer's disease, Hum Mol Genet 6 (1997), 1639-1646.
37. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, S.D. Schmidt, M.A. Chishti, P. Horne, D. Heslin, J. French, H.T. Mount, R.A. Nixon, M. Mercken, C. Bergeron, P.E. Fraser, P. St George-Hyslop and D. Westaway, A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature 408 (2000), 979-982.
38. L.A. Kotilinek, B. Bacskai, M. Westerman, T. Kawarabayashi, L. Younkin, B.T. Hyman, S. Younkin and K.H. Ashe, Reversible memory loss in a mouse transgenic model of Alzheimer's disease, J Neurosci 22 (2002), 6331-6335.
39. M.P. Lambert, P.T. Velasco, L. Chang, K.L. Viola, S. Fernandez, P.N. Lacor, D. Khuon, Y. Gong, E.H. Bigio, P. Shaw, F.G. De Felice, G.A. Krafft and W.L. Klein, Monoclonal antibodies that target pathological assemblies of Abeta, J Neurochem 100 (2007), 23-35.
40. E.B. Lee, L.Z. Leng, B. Zhang, L. Kwong, J.Q. Trojanowski, T. Abel and V.M. Lee, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, J Biol Chem 281 (2006), 4292-4299.
41. C.A. Lemere, R. Maron, E.T. Spooner, T.J. Grenfell, C. Mori, R. Desai, W.W. Hancock, H.L. Weiner and D.J. Selkoe, Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice, Ann N Y Acad Sci 920 (2000), 328-331.
42. C.A. Lemere, E.T. Spooner, J.F. Leverone, C. Mori and J.D. Clements, Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants, Neurobiol Aging 23 (2002), 991-1000.
43. J.F. Leverone, E.T. Spooner, H.K. Lehman, J.D. Clements and C.A. Lemere, Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting", Vaccine 21 (2003), 2197-2206.
44. J. Lewis, E. McGowan, J. Rockwood, H. Melrose, P. Nacharaju, M. Van Slegtenhorst, K. Gwinn-Hardy, M. Paul Murphy, M. Baker, X. Yu, K. Duff, J. Hardy, A. Corral, W.L. Lin, S.H. Yen, D.W. Dickson, P. Davies and M. Hutton, Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein, Nat Genet 25 (2000), 402-405.
45. I.T. Lott and E. Head, Alzheimer disease and Down syndrome: factors in pathogenesis, Neurobiol Aging 26 (2005), 383-389.
46. M. Maier, T.J. Seabrook and C.A. Lemere, Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G), Vaccine 23 (2005), 5149-5159.
47. E. Masliah, L. Hansen, A. Adame, L. Crews, F. Bard, C. Lee, P. Seubert, D. Games, L. Kirby and D. Schenk, Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease, Neurology 64 (2005), 129-131.
48. D. Moechars, I. Dewachter, K. Lorent, D. Reverse, V. Baekelandt, A. Naidu, I. Tesseur, K. Spittaels, C.V. Haute, F. Checler, E. Godaux, B. Cordell and F. Van Leuven, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J Biol Chem 274 (1999), 6483-6492.
49. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon and G.W. Arendash, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature 408 (2000), 982-985.
50. D.A. Morrissette and F.M. LaFerla, Stereological quantification of neuronal cells in 3xTg-AD mice, Soc Neurosci Abstr (2007), Program No. 888.8.
51. N. Movsesyan, A. Ghochikyan, M. Mkrtichyan, I. Petrushina, H. Davtyan, P.B. Olkhanud, E. Head, A. Biragyn, D.H. Cribbs and M.G. Agadjanyan, Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy, PLoS ONE 3 (2008), e2124.
52. K.L. Newell, B.T. Hyman, J.H. Growdon and E.T. Hedley-Whyte, Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease, J Neuropathol Exp Neurol 58 (1999), 1147-1155.
53. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham and R.O. Weller, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report, Nat Med 9 (2003), 448-452.
54. J.A. Nicoll, E. Barton, D. Boche, J.W. Neal, I. Ferrer, P. Thompson, C. Vlachouli, D. Wilkinson, A. Bayer, D. Games, P. Seubert, D. Schenk and C. Holmes, Abeta species removal after abeta42 immunization, J Neuropathol Exp Neurol 65 (2006), 1040-1048.
55. J. Nunan and D.H. Small, Regulation of APP cleavage by alpha-, beta- and gamma-secretases, FEBS Lett 483 (2000), 6-10.
56. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari and F.M. LaFerla, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron 39 (2003), 409-421.
57. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank and C. Hock, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology 61 (2003), 46-54.
58. D.M. Paresce, R.N. Ghosh and F.R. Maxfield, Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor, Neuron 17 (1996), 553-565.
59. M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P.M. Mathews and M. Jucker, Cerebral hemorrhage after passive anti-Abeta immunotherapy, Science 298 (2002), 1379.
60. M.M. Racke, L.I. Boone, D.L. Hepburn, M. Parsadainian, M.T. Bryan, D.K. Ness, K.S. Piroozi, W.H. Jordan, D.D. Brown, W.P. Hoffman, D.M. Holtzman, K.R. Bales, B.D. Gitter, P.C. May, S.M. Paul and R.B. DeMattos, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta, J Neurosci 25 (2005), 629-636.
61. S. Radaev and P.D. Sun, Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors, J Biol Chem 276 (2001), 16478-16483.
62. J. Rogers, L.F. Lue, D.G. Walker, S.D. Yan, D. Stern, R. Strohmeyer and C.J. Kovelowski, Elucidating molecular mechanisms of Alzheimer's disease in microglial cultures, Ernst Schering Res Found Workshop (2002), 25-44.
63. A. Rovelet-Lecrux, D. Hannequin, G. Raux, N. Le Meur, A. Laquerriere, A. Vital, C. Dumanchin, S. Feuillette, A. Brice, M. Vercelletto, F. Dubas, T. Frebourg and D. Campion, APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy, Nat Genet 38 (2006), 24-26.
64. A. Rovelet-Lecrux, T. Frebourg, H. Tuominen, K. Majamaa, D. Campion and A.M. Remes, APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage, J Neurol Neurosurg Psychiatry 78 (2007), 1158-1159.
65. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games and P. Seubert, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature 400 (1999), 173-177.
66. V.E. Schijns, Immunological concepts of vaccine adjuvant activity, Curr Opin Immunol 12 (2000), 456-463.
67. T.J. Seabrook, L. Jiang, K. Thomas and C.A. Lemere, Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice, J Neuroinflammation 3 (2006), 14.
68. K. Sleegers, N. Brouwers, I. Gijselinck, J. Theuns, D. Goossens, J. Wauters, J. Del-Favero, M. Cruts, C.M. van Duijn and C. Van Broeckhoven, APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy, Brain 129 (2006), 2977-2983.
69. B. Solomon, R. Koppel, D. Frankel and E. Hanan-Aharon, Disaggregation of Alzheimer beta-amyloid by site-directed mAb, Proc Natl Acad Sci U S A 94 (1997), 4109-4112.
70. C. Sturchler-Pierrat, D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, S. Rothacher, B. Ledermann, K. Burki, P. Frey, P.A. Paganetti, C. Waridel, M.E. Calhoun, M. Jucker, A. Probst, M. Staufenbiel and B. Sommer, Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, Proc Natl Acad Sci U S A 94 (1997), 13287-13292.
71. R.E. Tanzi, D.M. Kovacs, T.W. Kim, R.D. Moir, S.Y. Guenette and W. Wasco, The gene defects responsible for familial Alzheimer's disease, Neurobiol Dis 3 (1996), 159-168.
72. P.R. Turner, K. O'Connor, W.P. Tate and W.C. Abraham, Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory, Prog Neurobiol 70 (2003), 1-32.
73. V. Vasilevko, F. Xu, M.L. Previti, W.E. Van Nostrand and D.H. Cribbs, Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice, J Neurosci 27 (2007), 13376-13383.
74. D.M. Walsh and D.J. Selkoe, A beta oligomers - a decade of discovery, J Neurochem 101 (2007), 1172-1184.
75. J.B. Weinberg, M.A. Misukonis, P.J. Shami, S.N. Mason, D.L. Sauls, W.A. Dittman, E.R. Wood, G.K. Smith, B. McDonald, K.E. Bachus and et al., Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages, Blood 86 (1995), 1184-1195.
76. D.M. Wilcock, M.N. Gordon, K.E. Ugen, P.E. Gottschall, G. DiCarlo, C. Dickey, K.W. Boyett, P.T. Jantzen, K.E. Connor, J. Melachrino, J. Hardy and D. Morgan, Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels, DNA Cell Biol 20 (2001), 731-736.
77. D.M. Wilcock, G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K.E. Ugen, M.N. Gordon and D. Morgan, Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation, J Neurosci 23 (2003), 3745-3751.
78. D.M. Wilcock, S.K. Munireddy, A. Rosenthal, K.E. Ugen, M.N. Gordon and D. Morgan, Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration, Neurobiol Dis 15 (2004), 11-20.
79. D.M. Wilcock, A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M.J. Freeman, M.N. Gordon and D. Morgan, Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition, J Neurosci 24 (2004), 6144-6151.
80. D.M. Wilcock, A. Rojiani, A. Rosenthal, S. Subbarao, M.J. Freeman, M.N. Gordon and D. Morgan, Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J Neuroinflammation 1 (2004), 24.
81. D.M. Wilcock, J. Alamed, P.E. Gottschall, J. Grimm, A. Rosenthal, J. Pons, V. Ronan, K. Symmonds, M.N. Gordon and D. Morgan, Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice, J Neurosci 26 (2006), 5340-5346.
82. D.M. Wilcock, M.R. Lewis, W.E. Van Nostrand, J. Davis, M.L. Previti, N. Gharkholonarehe, M.P. Vitek and C.A. Colton, Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2, J Neurosci 28 (2008), 1537-1545.
83. R.A. Willis, W.J. Bowers, M.J. Turner, T.L. Fisher, C.S. Abdul-Alim, D.F. Howard, H.J. Federoff, E.M. Lord and J.G. Frelinger, Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice, Hum Gene Ther 12 (2001), 1867-1879.